Michael F MacLean
CIK 1383731 · Chief Financial Officer · last filed 2026-04-03
Michael F MacLean is a Chief Financial Officer who has filed 59 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CAMP, was dated Apr 3, 2026. Across all open-market trades the lifetime net is −$16.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.91M
6
59
-$16.65M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $3.42 | — | $0 | 1 | 2026-04-03 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Financial Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Chief Financial Officer | 62,025 | $11.49 | $712.7K | -$15.13M | 18 | 2026-01-23 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 7 | 2025-07-28 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Chief Financial Officer | 48,000 | — | — | $0 | 6 | 2020-01-16 |
| BIIB | SVP, Chief Accounting Officer | 10,681 | $205.61 | $2.20M | -$1.52M | 21 | 2010-10-04 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-03 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −133,977 | $0 | EDGAR |
| 2026-01-23 | RNA | Sell (S) | −4,542 | -$329.1K | EDGAR |
| 2026-01-09 | RNA | Sell (S) | −1,974 | -$142.6K | EDGAR |
| 2025-08-15 | RNA | Sell (S) | −30,914 | -$1.32M | EDGAR |
| 2025-08-06 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −30,914 | -$1.18M | EDGAR |
| 2025-07-28 | Verve Therapeutics, Inc. (VERV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-06 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-21 | RNA | Sell (S) | −7,935 | -$246.4K | EDGAR |
| 2025-01-23 | RNA | Sell (S) | −3,287 | -$94.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.